PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Sep 04, 2018

byncaipen

Ophthalmology | Transplants

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company...Read more

Jan 10, 2018

byncaipen

Biomanufacturing | Transplants

ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP® on Monoclonal Antibody Production and Bone Marrow Recovery

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.